Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | DCC-3116 |
Trade Name | |
Synonyms | DCC 3116|DCC3116 |
Drug Descriptions |
DCC3116 selectively inhibits ULK1/2, leading to decreased phosphorylation of its substrate ATG13 and inhibition of autophagosome formation, and may lead to inhibition of tumor cell growth (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B129). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C180331 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Afatinib + DCC-3116 | Afatinib DCC-3116 | 0 | 0 |
Binimetinib + DCC-3116 | Binimetinib DCC-3116 | 0 | 1 |
Cetuximab + DCC-3116 + Encorafenib | Cetuximab DCC-3116 Encorafenib | 0 | 1 |
DCC-3116 | DCC-3116 | 0 | 1 |
DCC-3116 + Osimertinib | DCC-3116 Osimertinib | 0 | 0 |
DCC-3116 + Ripretinib | DCC-3116 Ripretinib | 0 | 1 |
DCC-3116 + Sotorasib | DCC-3116 Sotorasib | 0 | 1 |
DCC-3116 + Trametinib | DCC-3116 Trametinib | 0 | 1 |